TG Therapeutics Inc. (NASDAQ:TGTX) shares were up 4.5% during trading on Tuesday . The stock traded as high as $6.56 and last traded at $6.46, with a volume of 172,037 shares trading hands. The stock had previously closed at $6.18.

Several research analysts recently commented on TGTX shares. Roth Capital reissued a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a research report on Wednesday, August 10th. S&P Equity Research reduced their price target on TG Therapeutics from $7.15 to $6.40 in a research report on Wednesday, August 24th. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Finally, SunTrust Banks Inc. began coverage on TG Therapeutics in a research report on Friday, May 27th. They issued a “buy” rating and a $18.00 price objective for the company. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $20.71.

The firm has a 50 day moving average of $5.99 and a 200-day moving average of $7.64. The stock’s market capitalization is $347.43 million.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. Equities analysts predict that TG Therapeutics Inc. will post ($1.23) earnings per share for the current year.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.